« Return to News | R&D Trends

Lilly awards IDRI $4 million in tuberculosis research funding

Tuesday, November 22, 2011 10:55 AM

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly. The funding will support IDRI’s continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB).

IDRI is a member of the Lilly TB Drug Discovery Initiative, a unique not-for-profit public-private partnership founded in 2007. Combining the efforts of government agencies, philanthropic organizations, pharmaceutical companies, universities, and other research institutions, the Initiative aims to accelerate early stage drug discovery in the search for new TB treatments. This additional $4.2 million in funding brings Eli Lilly’s total support of early stage TB drug discovery efforts through IDRI to $20 million.

"While preventable and treatable, nearly 1.5 million people die from TB and MDR-TB every year," said John C. Lechleiter, Ph.D., Eli Lilly chairman, president and chief executive officer. "Today's TB drugs are decades old and must be taken for extended periods of time, which present challenges for patients and health care providers. More effective medicines with fewer side effects are desperately needed."

Philip Hipskind, senior research fellow at Eli Lilly said, “Through the Initiative, we have forged strong links with IDRI’s scientists with the aim of leveraging the unique drug discovery capabilities of each organization.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.